CVRx Inc (CVRX)vsMerck & Company Inc (MRK)
CVRX
CVRx Inc
$7.51
+9.32%
HEALTHCARE · Cap: $209.97M
MRK
Merck & Company Inc
$109.18
-1.60%
HEALTHCARE · Cap: $274.03B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 114657% more annual revenue ($65.01B vs $56.65M). MRK leads profitability with a 28.1% profit margin vs -94.1%. MRK earns a higher WallStSmart Score of 59/100 (C).
CVRX
Avoid22
out of 100
Grade: F
MRK
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+69.5%
Fair Value
$19.96
Current Price
$7.51
$12.45 discount
Margin of Safety
-13.2%
Fair Value
$96.48
Current Price
$109.18
$12.70 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Areas to Watch
4.4% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -96.6% — below average capital efficiency
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : CVRX
CVRX has a balanced fundamental profile.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bear Case : CVRX
The primary concerns for CVRX are Revenue Growth, EPS Growth, Market Cap.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
CVRX profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.
CVRX carries more volatility with a beta of 1.12 — expect wider price swings.
MRK is growing revenue faster at 5.0% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (59/100 vs 22/100), backed by strong 28.1% margins. CVRX offers better value entry with a 69.5% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CVRx Inc
HEALTHCARE · MEDICAL DEVICES · USA
CVRx, Inc. develops implantable technology for the treatment of patients with high blood pressure / hypertension and heart failure.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?